Literature DB >> 8903511

Human CD38, a cell-surface protein with multiple functions.

K Mehta1, U Shahid, F Malavasi.   

Abstract

Human CD38 is a nonlineage-restricted type II transmembrane glycoprotein that has emerged as a multifunctional protein in recent years. It can serve as an ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose, a recently identified Ca2+ mobilizing agent that acts independently of inositol triphosphate. The enzymatic functions of CD38 probably contribute to an array of its immunoregulatory functions. The release of soluble CD38 and the ability of membrane-bound CD38 to become internalized in response to appropriate stimuli suggest that extracellular and intracellular roles for this protein are equally plausible. Ligation of CD38 with agonistic antibodies induces diverse effects in hematopoietic cells that range from growth stimulation to induction and prevention from apoptosis, induction of cytokines, activation of kinases, and phosphorylation of certain proteins. These observations suggest that CD38 may serve as receptor for an as yet unidentified ligand. Other molecules that share significant structural and functional homology to CD38 have been identified in humans and mice, suggesting that these molecules may represent a new family of proteins. Understanding the role of CD38 in certain pathological conditions such as myeloma, X-linked agammaglobulinemia, and HIV infection may provide insight into its physiological functions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903511     DOI: 10.1096/fasebj.10.12.8903511

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  51 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38 signalling.

Authors:  C Cakir-Kiefer; H Muller-Steffner; N Oppenheimer; F Schuber
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

3.  Structure and enzymatic functions of human CD38.

Authors:  Hon Cheung Lee
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

4.  Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.

Authors:  Jean Kwun; Marie Matignon; Miriam Manook; Soulef Guendouz; Vincent Audard; David Kheav; Elsa Poullot; Chantal Gautreau; Brian Ezekian; Diane Bodez; Thibault Damy; Laureline Faivre; Dehbia Menouch; Janghoon Yoon; Jaeberm Park; Karim Belhadj; Dongfeng Chen; Alyssa M Bilewski; John S Yi; Bradley Collins; Mark Stegall; Alton B Farris; Stuart Knechtle; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2019-06-21       Impact factor: 10.121

Review 5.  An update on the role of daratumumab in the treatment of multiple myeloma.

Authors:  Caitlin Costello
Journal:  Ther Adv Hematol       Date:  2016-11-24

6.  Novel peptide inhibitor of ecto-ADP-ribosyl cyclase of bone marrow stromal cell antigen-1 (BST-1/CD157).

Authors:  A Sato; S Yamamoto; K Ishihara; T Hirano; H Jingami
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

7.  Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Authors:  T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg
Journal:  Cancer Immunol Immunother       Date:  2011-03-05       Impact factor: 6.968

8.  Generation of cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate by CD38 for Ca2+ signaling in interleukin-8-treated lymphokine-activated killer cells.

Authors:  So-Young Rah; Mazhar Mushtaq; Tae-Sik Nam; Suhn Hee Kim; Uh-Hyun Kim
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

Review 9.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

10.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.

Authors:  Carlo Calissano; Rajendra N Damle; Gregory Hayes; Elizabeth J Murphy; Marc K Hellerstein; Carol Moreno; Cristina Sison; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-09-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.